Brazilian Journal of Otorhinolaryngology
versão impressa ISSN 1808-8694
GANANCA, Maurício Malavasi et al. Betahistine in the treatment of tinnitus in patients with vestibular disorders. Braz. j. otorhinolaryngol. (Impr.) [online]. 2011, vol.77, n.4, pp. 499-503. ISSN 1808-8694. http://dx.doi.org/10.1590/S1808-86942011000400014.
Betahistine is a medicine used to treat vestibular disorders that has also been used to treat tinnitus. AIM: To assess the effects of betahistine on tinnitus in patients with vestibular disorders. MATERIAL AND METHOD: Retrospective data were collected from patient records for individuals presenting with vestibular dysfunction and tinnitus. Patients included had received betahistine 48 mg/day and clinical outcomes were compared with a control group comprising individuals who were unable to receive betahistine due to gastritis, ulcers, pregnancy, asthma or hypersensitivity to the drug. Patients underwent control of any aggravating factors and also standard vestibular exercises as a basis for treatment. The intensity, frequency and duration of tinnitus were assessed on the first day of dosing and after 120 days of treatment. Clinical improvement was defined as a total or partial reduction of tinnitus after treatment. RESULTS: Clinical improvement was observed in 80/262 (30. 5%) of patients treated with betahistine and 43/252 (17. 1%) of control patients. Betahistine significantly (p<0. 0001) improved tinnitus in treated individuals. CONCLUSIONS: The daily dosage of 48 mg of betahistine during 120 consecutive days is useful to reduce or eliminate tinnitus in patients with vestibular disorders
Palavras-chave : dizziness; medication therapy management; tinnitus; vertigo.